Mode
Text Size
Log in / Sign up

ROP incidence declined over 10 years in Chinese preterm infants, with no Type 1 cases in larger infants after 2018Why a Common Cause of Premature-Baby Blindness Is Steadily Disappearing

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note declining ROP trends in this Chinese cohort, but confirm in broader populations before changing practice.

This single-center retrospective study analyzed 10-year trends (2014-2023) in retinopathy of prematurity (ROP) incidence among 603 premature infants undergoing ROP screening in Sichuan, China. The study compared biennial periods to assess changes in ROP and Type 1 ROP incidence, along with associated clinical factors and screening strategies.

The main results showed overall ROP incidence declined from 22.8% to 16.5% over the study period, representing 116 of 603 infants. Type 1 ROP incidence declined from 5.9% to 4.2%, affecting 31 infants. Notably, no Type 1 ROP occurred in infants with birth weight >1,500 g or gestational age >32 weeks after 2018. Statistical significance measures (p-values, confidence intervals) for these declines were not reported.

Safety and tolerability data were not reported in the study. Key limitations include the single-center, retrospective design and lack of reported statistical testing for observed trends. The study population was limited to one region of China, which may limit generalizability to other settings with different neonatal care practices.

For clinical practice, these findings suggest potential improvements in neonatal care may be associated with declining ROP rates in this specific population. However, the observational nature of the data precludes causal conclusions. The absence of Type 1 ROP in larger, more mature infants after 2018 may inform local screening protocol discussions, but broader validation is needed before changing established screening guidelines.

The eye condition that quietly threatens preemie vision

Babies born too early face many risks. Among the more serious is a condition affecting the back of the eye called retinopathy of prematurity, or ROP. In its severe form, it can cause permanent vision loss or blindness if not caught and treated.

For decades, it was a major cause of childhood blindness worldwide. A new study from China shows just how much that picture is changing.

ROP develops when the blood vessels in a preemie's retina don't grow normally. Those abnormal vessels can scar the retina and, in the worst cases, pull it loose from the back of the eye.

The condition is treatable when caught early — typically with laser therapy or injections that calm the abnormal vessel growth. But treatment depends on screening. Babies born below certain birth weight or gestational age cutoffs need careful eye exams in the weeks after birth.

How well NICUs catch and treat ROP shapes long-term vision outcomes for thousands of children each year.

The old way versus the new way

For years, ROP was relatively common in NICUs. As survival of very preterm babies improved, more infants lived through the critical window when ROP develops, and case numbers stayed high.

Two trends have started shifting the picture. First, NICU oxygen management has become more carefully calibrated. Too much oxygen drives ROP; too little harms the lungs. Tighter targeting of oxygen levels has reduced ROP risk without compromising lung development. Second, screening protocols have been refined to catch cases earlier and direct treatment more precisely.

Together, these changes appear to be reducing ROP rates over time.

How ROP develops in tiny eyes

Imagine a road network being built across a landscape. In a healthy full-term baby, the roads — blood vessels in the eye — finish growing in a steady, orderly way before birth.

In a premature baby, the roads stop being built halfway. Then suddenly, after birth, they start growing again — but in a chaotic, urgent way that can damage the surrounding terrain.

When NICU teams give a preemie just enough oxygen — not too much, not too little — the road-building tends to resume more normally. When oxygen is poorly calibrated, the building goes haywire and damages the retina.

The study snapshot

The team analyzed records of 603 premature infants screened for ROP at a single hospital in Sichuan, China, between 2014 and 2023. They divided the period into five two-year windows and calculated incidence rates by birth weight and gestational age in each one.

Over the 10-year window, overall ROP incidence dropped from about 23% to 17%. The more dangerous Type 1 form — the kind that needs treatment — dropped from about 6% to 4%.

The most striking finding was about the babies who developed serious ROP at all. After 2018, no Type 1 ROP cases were observed in babies weighing more than 1,500 grams or born after more than 32 weeks of pregnancy. The trend was statistically significant.

In other words, the more mature preemies — the ones closer to a full pregnancy — increasingly didn't develop sight-threatening ROP at all. Severe ROP became concentrated among the smallest, most premature infants.

This doesn't mean screening should be reduced. Catching the rare cases that still occur remains essential.

Where this fits in the bigger picture

The decline in ROP is a quiet success story of modern neonatal medicine. It reflects steady improvements in oxygen management, ventilator strategies, nutrition, and infection control in NICUs.

The pattern seen in this Chinese hospital matches what's been reported in NICUs across many high- and middle-income countries. In low-income settings, however, ROP rates often remain high because the oxygen management tools and screening infrastructure are less developed.

This is one of the conditions where global health gaps remain stark.

If your baby was born prematurely and has been recommended for ROP screening, follow through on every appointment. Even with declining overall rates, the babies most at risk are exactly the ones who need screening.

If you have older preemies who had ROP screening years ago, occasional eye exams through childhood are still wise to monitor for late effects on vision.

For families weighing whether to push for early discharge, the regular eye exams in the weeks after birth are not optional. Skipping them is one of the few ways severe ROP still slips by undetected.

This study covers a single hospital in one region. Other regions, especially those with different screening practices or NICU protocols, may have different patterns. The decline in ROP also depends on how reliably the screening criteria identified at-risk babies — changes in those criteria could affect the apparent trend.

Continued improvements in oxygen targeting, NICU care, and screening tools should keep ROP rates falling. New imaging technologies — including artificial intelligence to help interpret retinal scans — are being tested to make screening faster and more accurate. The biggest remaining gains are likely in low-resource settings, where many preemies still lack reliable access to the existing standards of care.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveTo analyze the 10-year incidence trend of retinopathy of prematurity (ROP) in Sichuan, China, and explore associated clinical factors and screening strategies.MethodsIn this single-center retrospective study, 603 premature infants undergoing ROP screening between 2014 and 2023 were included. Incidence rates were calculated across five biennial periods, stratified by birth weight and gestational age. Cochran-Armitage test assessed trends; a decision model evaluated screening thresholds; correlation/regression analyses identified clinical associations.ResultsOverall ROP incidence was 19.2% (116/603); Type 1 ROP incidence was 5.1% (31/603). ROP incidence declined from 22.8% to 16.5%, and Type 1 ROP from 5.9% to 4.2% over the study period. No Type 1 ROP occurred in infants >1,500 g or >32 weeks after 2018, with a statistically significant downward trend (P 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.